Showing papers by "Geoffrey C. Gurtner published in 2006"
TL;DR: Replacement of the donor graft vasculature by endothelial and endothelial progenitor cells from the recipient along preexisting channels is the predominant mechanism for skin graft revascularization.
Abstract: Background:Long-term survival of a skin graft is dependent on eventual revascularization. The authors’ aim in the present study was to determine whether skin graft vascularization occurs by (1) simple reconnection of vessels, (2) ingrowth of recipient vasculature, (3) outgrowth of donor-derived vess
114 citations
01 Sep 2006
TL;DR: Calreticulin profoundly affects the wound healing process by recruiting cells essential for repair into the wound, stimulating cell growth, and increasing extracellular matrix production.
Abstract: Calreticulin (CRT), an intracellular chaperone protein crucial for the proper folding and transport of proteins through the endoplasmic reticulum, has more recent acclaim as a critical regulator of extracellular functions, particularly in mediating cellular migration and as a requirement for phagocytosis of apoptotic cells. Consistent with these functions, we show that the topical application of CRT has profound effects on the process of wound healing by causing a dose-dependent increase in epithelial migration and granulation tissue formation in both murine and porcine normal and impaired animal models of skin injury. These effects of CRT are substantiated, in vitro, as we show that CRT strongly induces cell migration/wound closure of human keratinocytes and fibroblasts, using a wound/scratch plate assay, and stimulates cellular proliferation of human keratinocytes, fibroblasts, and vascular endothelial cells, providing mechanistic insight into how CRT functions in repair. Similarly, in both animal models, the histology of the wounds show marked proliferation of basal keratinocytes and dermal fibroblasts, dense cellularity of the dermis with notably increased numbers of macrophages and well-organized collagen fibril deposition. Thus, CRT profoundly affects the wound healing process by recruiting cells essential for repair into the wound, stimulating cell growth, and increasing extracellular matrix production.
60 citations
TL;DR: The results indicate that hemangiomas are not microchimeric in origin, providing further insight into the origin of a tumor whose pathogenesis remains elusive.
47 citations
TL;DR: Targeting gene delivery with minimal systemic toxicity is essential for successful gene therapy and this form of “biological brachytherapy” provides a new opportunity to deliver targeted therapeutic transgenes to patients undergoing reconstructive surgery and allows microvascular free flaps to perform therapeutic and reconstructive functions.
Abstract: Background:Gene therapy for cancer holds enormous therapeutic promise, but its clinical application has been limited by the inability to achieve targeted, high-level transgene expression with limited systemic toxicity. The authors have developed a novel method for delivering genes to microvascular f
29 citations
Patent•
05 Dec 2006TL;DR: One aspect of the present invention relates to a method of treating or preventing pathologic effects of hyperglycemia and increased fatty acid flux in a subject in need of such treatment or preventive therapy as discussed by the authors.
Abstract: One aspect of the present invention relates to a method of treating or preventing pathologic effects of hyperglycemia ahd/or increased fatty acid flux in a subject in need of such treatment or preventive therapy. This method involves administering a composition containing a therapeutically effective amount of a ROS inhibitor to a subject in need thereof.
2 citations
1 citations
TL;DR: An ex vivo technique to transduce microvascular free flaps with a recombinant adenoviral vector which expresses the anti-tumor cytokine IL2 is developed, able to target treatment specifically to the required area without eliciting the known toxic effects associated with systemic administration of IL2.
Abstract: iNTRODUCTiON: The widespread clinical use of cancer gene therapy has been prevented by the inability to deliver high levels of local transgene expression while limiting the systemic host response. Our lab has developed an ex vivo technique to transduce microvascular free flaps with a recombinant adenoviral vector which expresses the anti-tumor cytokine IL2. Using this approach, we are able to target treatment specifically to the required area without eliciting the known toxic effects associated with systemic administration of IL2.